Patent intelligence · US
US 8815246
Fc receptor binding proteins
Fc receptor binding proteins
Patent details — US 8815246
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 26, 2014
- Expiration
- Aug 21, 2034
- Applicant
- Syntonix Pharmaceuticals, Inc.
- Claims
- 12
- CPC classes
- A61K, A61K2039/505, A61K49/0058, A61K49/16
Quick answer
US 8815246 (Fc receptor binding proteins) is held by Syntonix Pharmaceuticals, Inc.. Status: granted. Granted Aug 26, 2014. Expires Aug 21, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Syntonix Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K2039/505, A61K49/0058, A61K49/16, A61K51/1027, A61P
More from Syntonix Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12383733
Iontophoresis-based patch type medicine absorption device
granted -
US 12365879
Synthetic chimeric poxviruses
granted -
US 12304901
Selective ligands for tau aggregates
granted -
US 12156897
Magnesium-containing oxytocin formulations and methods of use
granted -
US 12156864
Analogs of cyclobenzaprine and amitryptilene
granted -
US 12097183
Pharmaceutical composition for treating migraine
granted -
US 12090139
Formulations comprising triptan compounds
granted -
US 11998516
Methods and compositions for treating depression using cyclobenzaprine
granted
Frequently asked questions
What is US patent 8815246?
US 8815246 (Fc receptor binding proteins) is held by Syntonix Pharmaceuticals, Inc.. Status: granted. Granted Aug 26, 2014. Expires Aug 21, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8815246?
Syntonix Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 86 pharmaceutical patents for this assignee.
When does US 8815246 expire?
Our index shows an expiration date of Aug 21, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.